Objective-Defects in angiogenesis/vasculogenesis or vessel repair are major complications of coronary artery disease (CAD). Endothelial progenitor cells (EPCs) play a fundamental role in postnatal vascular repair and CAD. The role of microRNAs in CAD pathogenesis and their potential as biomarkers remain to be elucidated. Approach and Results-MicroRNA-31 (miR-31) level in both the plasma and EPCs of patients with CAD is found lower.
C oronary artery disease (CAD) still ranks as one of the most fatal diseases worldwide despite advances in prevention and treatment. A progressive impairment of endothelial function and integrity starts a cascade of events that leads to microcirculation damage, atherosclerosis, CAD, and other common cardiovascular disorders including myocardial infarction, heart failure, stroke, and peripheral arterial disease. 1 Developing new early diagnostic biomarkers and therapeutic strategies based on the endothelial lineage of cells is therefore of clinical significance and important to pharmaceutical companies.
Adult stem cells fuel the renewal of many tissues. Convincing evidence suggests that neovascularization in adults is not solely the result of proliferation of local endothelial cells (angiogenesis), but also involves bone marrow-derived circulating endothelial progenitor cells (EPCs). EPCs, which are derived from hematopoietic stem cells, are capable of forming new blood vessels (vasculogenesis) even in the absence of a pre-existing vessel network. 2 The number of circulating EPCs in patients has been reported to be negatively correlated with the progression of coronary heart disease, hypertension, diabetes mellitus, and aging. [3] [4] [5] Increased circulating CD31 + / annexin V + apoptotic microparticles and decreased circulating EPC levels have also been detected in hypertensive patients with microalbuminuria. 6 In terms of mechanisms, several studies have reported that inflammation influences the mobilization and differentiation of EPCs. 5 EPCs are currently being tested in several different clinical settings including the repair of damaged microcirculation, the regeneration of ischemic tissues such as in stroke, 7 and the bioengineering of vascular grafts (www.clinicaltrials.gov).
In addition to the number of circulating EPCs present, the regulation of postnatal angiogenesis/vasculogenesis also depends on the activity of mobilized EPCs. 8 In addition to the effects of protein-coding genes, the expression of various different microRNAs (miRNAs, miRs) also plays a critical role in the clinical course of CAD. miRNAs are a class of endogenous, small, noncoding, single-stranded RNAs of ≈22 nucleotides in length. The mature miRNAs negatively regulate gene expression by targeting specific mRNAs for cleavage or translational repression. Detecting the levels of tissue miRNAs, as well as the levels of circulating miRNAs in body fluids, is considered to be a potential approach to identifying new disease biomarkers and novel drug targets. [9] [10] [11] Many proangiogenic and antiangiogenic miRNAs have been pinpointed. Examples such as miR-221 and miR-222, which are transcribed from the same miR-221/222 cluster, have been shown to be able to modulate the angiogenic properties of human umbilical vein endothelial cells by targeting c-Kit and endothelial NO synthase. 12, 13 miR-221/222 levels in EPCs are significantly higher in patients with CAD. 14, 15 miR-10a* and miR-21 are also known to modulate EPC senescence via the suppression of high-mobility group A2. 16 miR-10b and miR-196b, on the contrary, increase the activity of circulating EPCs. 17 Harris et al 18 showed that the expression of miR-126 inhibited vascular cell adhesion molecule-1 expression in endothelial cells and that decreased levels of endogenous miR-126 increased leukocyte adherence to endothelial cells, which suggests that miRNA is able to regulate adhesion molecule expression and provide additional control of vascular inflammation. Consistently, expression of miR-126 in EPCs, and also of miR-508-5p, has been shown to be associated with the prognosis of patients with chronic heart failure. 19 Overexpression of miR-31 in blood vessel endothelial cells promotes endothelial motility in vitro, 20 which suggests that miR-31 is a positive regulator of some fundamental endothelial functions. Other experiments have shown that miR-31 targets FAT atypical cadherin 4 (FAT4), a newly identified tumor suppressor, in both blood vessel and lymphatic vessel endothelial cells for inducing endothelial cell migration and invasion. 21 miR-31 also functions as a negative regulator of lymphatic vascular lineagespecific differentiation in vitro and vascular development in vivo by targeting prospero homeobox 1 (PROX1), a transcription factor that functions as a master regulator of lymphatic lineage-specific differentiation. 22 Recently, levels of miR-31 have been found to be significantly higher in EPCs with better angiogenic ability: EPCs from cord blood are more active and express more miR-31 compared with those derived from peripheral blood (PB). 23 The pathological role and underlying mechanisms by which miR-31 affects cardiovascular diseases, however, have not been examined.
We hypothesized that miR-31, on top of its known physiological functions, also plays a crucial role in CAD pathogenesis. We examined levels of miR-31 in EPCs from diseased individuals and in the plasma of patients with CAD to evaluate its potential as a biomarker. How miR-31 regulates CAD EPC activity was also explored. Finally, we tested the possibility that restoring CAD EPC function by increasing miR-31 levels in diseased EPCs either by the transfection of oligonucleotide mimics of miR-31 or by far-infrared (FIR) treatment of ex vivo expanded EPCs.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Reduced miR-31 Levels in the Plasma and EPCs of Patients With CAD
Late EPCs from the PB of healthy donors (Hds) and patients with CAD were isolated and characterized as described. 24 Both healthy and diseased late EPCs have a cobblestone-like morphology ( Figure IA in the online-only Data Supplement). Both EPCs were confirmed as having endothelial lineage characteristics because both precursor cells were positive for acLDL (acetylated-low density lipoprotein) uptake ( Figure IB in the online-only Data Supplement). They also express similar levels of endothelial marker genes and the CD34 precursor gene in the fluorescence-activated cell sorter analysis ( Figure  IC in the online-only Data Supplement).
Next, the possible involvement of miR-31 in CAD pathogenesis was explored by detecting miR-31 levels in EPCs and the plasma from patients with CAD and from healthy control individuals. EPCs isolated from CAD cases were found to express less miR-31 than those from healthy controls ( Figure 1A , left). The levels of circulating miR-31 in plasma from patients with CAD were also significantly lower than in plasma from healthy controls ( Figure 1A , right). Overexpressing miR-31 in healthy EPCs increased EPC migration and the ability of EPCs to form microvascular tubes ( Figure 1B ), whereas knockdown of endogenous miR-31 in healthy EPCs hindered these abilities ( Figure 1C ). Notably, flow cytometric analysis showed clearly that the CAD EPCs expressed less vascular endothelial growth factor (VEGF) receptor 2/kinase insert domain receptor but more vascular endothelial-cadherin ( Figure in the online-only Data Supplement), which may reflect the migration activities of these cells. Most importantly, increasing miR-31 expression in CAD EPCs to a level that is compatible with that of healthy EPCs using miR-31 oligonucleotide agomirs ( Figure 1D ) rescued the migratory and tube formation activities of CAD EPCs to levels that are comparable with those of healthy EPCs ( Figure 1E and 1F).
miR-31 Regulates EPC Function via the Suppression of FAT4 and Thromboxane A2 Receptor
FAT4, a tumor suppressor, has been previously identified as a direct downstream target of miR-31 in mature lymphatic endothelial cells. 21 We examined whether the same scenario also occurs in EPCs. Increased expression of FAT4 was, as expected, found to be present in CAD EPCs (Figure 2A ). FAT4 levels were negatively correlated with those of miR-31 during overexpression and knockdown experiments using Hds' PB EPCs ( Figure 2B ). These observations implied that the dysregulation of the miR31-FAT4 axis contributes to defective CAD EPC activity. To better understand the mechanism underlying the activity of miR-31, we investigated new miR-31 downstream targets. miR-31 is more abundant in cord blood EPCs than in PB EPCs from healthy individuals 23 and is also more abundant in cord blood EPCs than in mature endothelial cells such as human umbilical vein endothelial cell (not shown). We aligned the genes downregulated in cord blood EPCs in comparison with PB EPCs 23 and human umbilical vein endothelial cells to predict miR-31 targets using the miRTar bioinformatics tool. 25 To further narrow down possible miR-31 targets, we also checked whether the target candidates had known antiangiogenic activity. A known antiangiogenic gene, thromboxane A2 (TBXA2) receptor (TBXA2R), fulfilled all these criteria ( Figure 2C , left). TBXA2R is a G protein-coupled receptor that is involved in platelet aggregation and endothelial cell migration. 26 Furthermore, TBXA2R is an important mediator of isoprostanes, which are the endogenously formed end products of lipid peroxidation and are known to inhibit VEGF-induced angiogenesis. 27 The involvement of TBXA2R in CAD pathogenesis has not been reported previously to our knowledge.
Microarray data showed that the level of TBXA2R is higher in mature endothelial cells ( Figure 2C , middle). We confirmed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) that the expression levels of TBXA2R are higher in both mature endothelial cells ( Figure 2C , right) and in CAD EPCs ( Figure 2D ) compared with healthy EPCs. The RNA and protein levels of TBXA2R were found to be decreased when miR-31 was overexpressed in healthy EPCs, but were increased when endogenous miR-31 was knocked down ( Figure 2E ). The direct repression of TBXA2R by miR-31 was explored using the luciferase reporter assay, and it was found that miR-31 is able to repress luciferase expression when the construct contained the TBXA2R 3′ untranslated region fused downstream of the luciferase gene ( Figure 2F , the wild-type group). Such repression could be reversed by mutating the predicted miR-31-binding site ( Figure 2F , the mutant group).
To further clarify the hierarchical relationship between miR-31 and TBXA2R, we compared the results of knocking down miR-31 with those of knocking down TBXA2R, either independently or in combination with miR-31 knockdown ( Figure 2G ). EPCs with reduced miR-31 showed poorer Figure 2G ). Similar results were found using the tube formation assay ( Figure 2H , right and Figure IIB in the online-only Data Supplement). These findings suggested that TBXA2R is also an important direct downstream target of miR-31. Knocking down TBXA2R did not alter miR-31 levels in EPCs ( Figure 2G , lanes 1 versus 3), which suggests that regulation of the miR31-TBXA2R pathway is not reciprocal.
Induction of miR-31, and Its Partner miR-720, in CAD EPCs by FIR Treatment
The aforementioned findings suggest that the restoration of miR-31 levels in diseased EPCs might have potential as a novel therapeutic strategy. Nevertheless, delivering miRNA-related biological drugs, such as synthetic oligonucleotide mimics in vivo, is still a major challenge. Therefore, we sought an alternative approach that might be able to stimulate and restore the expression of endogenous miR-31 in CAD EPCs. It has been reported that FIR treatment is able to boost EPC activity and angiogenesis both in vitro and in vivo. 28 We were able to confirm that FIR treatment not only induces cellular migration, microvascular formation, and endothelial NO synthase production in healthy EPCs ( Figure 3A and Figure IIIA in the online-only Data Supplement), but also restores migration and tube formation in CAD EPCs ( Figure 3B and Figure IIIB in the online-only Data Supplement). FIR irradiation was found to result in the upregulation of miR-31 accompanied with the downregulation of the miR-31 targets (FAT4 and TBXA2R) in healthy EPCs ( Figure 3C ). Treating CAD EPCs with FIR restored the expression of endogenous miR-31 to a level comparable with that of healthy EPCs ( Figure 3D ). Furthermore, FAT4 and TBXA2R levels were also suppressed by FIR in CAD EPCs ( Figure IIIC in the online-only Data Supplement). To clarify whether miR-31 mediates FIR-induced endothelial cell activation, we used healthy EPCs with knocked down endogenous miR-31 for the FIR treatment and analyzed their cell migration and microvascular formation abilities. It was confirmed that knocking down of miR-31 abolished the cell activities induced by FIR ( Figure 3E ).
To provide further mechanistic insights into the miR-31-mediated FIR functions, partner miRNAs to miR-31 that also respond to FIR treatment were explored. RNA extracted from FIR-treated PB EPCs were subjected into miRNA microarray analysis and 11 more miRNAs (in addition to miR-31) were found to be induced by FIR by ≥2-fold in these EPCs, with miR-720 as the most upregulated ( Figure IIID in the online-only Data Supplement). The increase in miR-720, miR-301a, and miR-7 levels induced by FIR in healthy EPCs was confirmed by RT-qPCR using independent batches of blood, and again miR-720 was found to be the most upregulated miRNA after FIR treatment ( Figure 3F ). Similarly, in CAD EPCs, miR-720 was the most significant induced miRNA by FIR ( Figure IIIE in the online-only Data Supplement). In the light of the above results, we speculated that there is a cross-talk between miR-31 and miR-720. In healthy EPCs, overexpression of miR-31 increased miR-720 levels ( Figure 3G , left), whereas knockdown of endogenous miR-31 resulted in a reduction of endogenous miR-720 ( Figure 3G , right). To further elucidate whether miR-31 mediates FIR induction of miR-720 in PB EPCs, we used healthy EPCs with knocked down endogenous miR-31 for the FIR treatment and analyzed levels of miR-720, as well as the transcript levels of FAT4 and TBXA2R. Knocking down of miR-31 abolished FIR-induced miR-720 induction ( Figure 
The New Angiogenic miRNA miR-720, Which Is Regulated by miR-31, Contributes to CAD EPC Activity
No report up to the present has suggested that miR-720 contributes to angiogenesis or to CAD pathogenesis. Similar to miR-31, miR-720 levels were found to be lower in both the EPCs and the plasma from patients with CAD ( Figure 3H ) compared with healthy EPCs. miR-720 levels in CAD EPCs could be restored by FIR to a level comparable with that of healthy EPCs ( Figure 4A ). Schopman et al 29 showed by in silico sequence alignment that the sequence annotated as miR-720 overlaps with that of tRNA Thr , which is encoded by the mitochondrion. Nevertheless, because of the short sequence that makes up miR-720, it is still possible to map miR-720 to other regions of human genome. We found that both the pre-miR-720 and miR-720 sequences could also be aligned to human chromosome 3 (chr3: 164059155-164059171; Figure  IVA in the online-only Data Supplement).
Before checking the angiogenic role and related mechanisms of miR-720, we examined whether miR-720 has the functional characteristics of an miRNA, such as a Dicer1dependent biogenesis, physical association with Argonaute proteins, and the ability to repress mRNA transcripts in a sequence-specific manner. We first checked the physical association of mature miR-720 with the Argonaute 2 protein by performing RT-qPCR assays on RNA immunoprecipitation (RIP) products brought down by an anti-Argonaute 2 antibody. Mature miR-720 was significantly enriched in anti-Argonaute 2 RIP products ( Figure VA in the onlineonly Data Supplement; miR-31 was included as a positive control). To validate our RIP-qPCR data, we extracted another 19 anti-Argonaute 1/2 immunoprecipitation small RNA sequencing results (RIP-seq, CLIP-seq [cross-linking immunoprecipitation-sequencing], or PAR-CLIP-seq [photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation-sequencing]; Figure IVB in the onlineonly Data Supplement), which correspond to 10 data sets, from the NCBI GEO database, and analyzed whether miR-720 was also significantly enriched in other anti-Argonaute 1/2 immunoprecipitation experiments. miR-720 signals were found to be enriched in 4 sequencing results, namely those obtained from HeLa cells, the Sup-T1 human T-cell lymphoblastic lymphoma cell line, and the BC-1 B-cell line ( Figure  IVC in the online-only Data Supplement). The pre-miR-720 sequence and RIP-seq reads that mapped onto matured miR-720 are shown in Figure IVD in the online-only Data Supplement.
We next examined whether biogenesis of miR-720 occurs in a Dicer1-dependent manner. When DICER1 RNAs were knocked down in healthy EPCs, less mature miR-720 could be detected by RT-qPCR. In contrast, pre-miR-720 transcripts were accumulated and increased ( Figure VB in the online-only Data Supplement). These results suggested that miR-720 maturation, just like other miRNAs recorded in the miRBase, follows the miRNA biogenesis rule set. Collectively, our findings support the hypothesis that miR-720, whether derived from tRNA Thr or from the site on human chromosome 3, has the features of an miRNA.
We evaluated the proangiogenic role of miR-720 in EPC from Hds and patients with CAD by functional assays. Overexpression of miR-720 agomirs in healthy EPCs promoted cell migration and microvasculature formation activities in vitro ( Figure 4B and Figure VC 
miR-720 Represses a Major Downstream Target, Vasohibin 1, in a Sequence-Specific Manner
To understand mechanisms related to the activity of miR-720 and to confirm that miR-720 has the characteristics of a functional miRNA, we analyzed the ability of miR-720 to repress mRNA transcripts in a sequence-specific manner. We mined candidate downstream targets of miR-720 by combining bioinformatics prediction with gene expression microarray data and targeting FIR-repressed genes in EPCs. Fifty-nine genes were predicted to be the direct targets of miR-720 ( Figure 4E ). Among these candidates, 4 genes (SUFU, vasohibin 1 [VASH1], PTK2, and MDM2) are known to be involved in angiogenesis or cell proliferation ( Figure 4E ). Using a new batch of healthy EPCs as an independent validation cohort, VASH1 was found to be the most significantly affected gene in terms of downregulation by FIR treatment ( Figure VE VASH1 belongs to a family of N-terminal prolactin fragments that inhibits angiogenesis and vascular functioning. 30, 31 VASH1 mRNA levels were found to be higher in CAD EPCs ( Figure 4F ) than in Hd EPCs. The protein and mRNA expression levels of VASH1 were negatively correlated with . Functional characteristics of microRNA-720 (miR-720) as a proangiogenic miRNA. A, Far-infrared (FIR) irradiation restored the expression of endogenous miR-720 in coronary artery disease (CAD) endothelial progenitor cells (EPCs) to a level similar to that in healthy EPCs. B and C, The proangiogenic effects of miR-720. Transwell cell migration (left) and tube formation assays (right) were conducted on healthy EPCs transfected with miR-720 mimics (B) or anti-miRs (C). The miR-720 expression level is shown in Figure VC in the online-only Data Supplement. D, CAD EPC motility (middle) and vasculogenesis (right) were returned to normal levels by restoring the miR-720 level (left). All histograms were graphed as mean±SD. E, A Venn diagram showing the principle by which candidate miR-720 targets were selected. F, Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) results show vasohibin 1 (VASH1) mRNA levels in EPCs from healthy donors (Hds) and patients with CAD. G and H, VASH1 is repressed directly by miR-720. G, The expression levels of VASH1 were detected by RT-qPCR and immunoblotting in EPCs transfected with miR-720 mimics or miR-720 anti-miRs. H, Left, Structure of the VASH1 transcript and the predicted duplex formed between the VASH1 coding sequence (CDS) and miR-720. Right, A luciferase reporter plasmid containing either the miR-720 wild-type (WT) binding site or a mutant (Mut) binding site was cotransfected with miR-720, and luciferase intensity was assessed 2 days after transfection. I, miR-720 (left) as well as VASH1 mRNA and protein levels (right) in EPCs transfected with various indicated oligonucleotides and plasmids are shown. J, Transwell migration (left) and tube formation (right) assays were conducted when knocking down VASH1 in miR-720-reduced EPCs. All histograms were graphed as mean±SD. Numbers above bars indicate the relative fold ratios. Significance levels, *P<0.05; **P<0.01; ***P<0.001. Scr indicates scramble control; UTR, untranslated region; and Vec, vector control.
the expression level of miR-720 ( Figure 4G ). Repression of VASH1 after FIR treatment was relieved by knockdown of miR-31 in Hd EPCs ( Figure VG in the online-only Data Supplement), which correlates with the scenario whereby miR-720 levels are reduced in FIR-treated Hd EPCs if endogenous miR-31 is knocked down ( Figure IIIF in the online-only Data Supplement).
Bioinformatics analysis using the miRTar webtool 25 indicated a putative miR-720 binding site in the coding region of VASH1 (Figure 4H, left) . Luciferase reporter assays were then used to confirm the direct repression of VASH1 by miR-720 ( Figure 4H, right) . The functional implications of this miR-720-VASH1 pairing with respect to EPC activity were then evaluated. We knocked down miR-720 and VASH1 in healthy EPCs and found that the reduction in miR-720 level in these EPCs led to an increase in cellular VASH1 levels and a reduction in EPC migration and tube formation ( Figure 4I and 4J, lane 2). In contrast, a reduction in VASH1 levels in EPCs stimulated cell migration and vasculogenesis ( Figure 4I and 4J, lane 3). Most importantly, when VASH1 was further knocked down in EPCs with reduced miR-720 expression, the migration and tube formation ability of EPCs was able to be restored ( Figure 4I and 4J, lane 2 versus 4).
Next, we examined to what extent VASH1 contributes to the effects of miR-31. When VASH1 transcripts were knocked down in miR-31-reduced EPCs, the angiogenic-related abilities of EPCs were restored from 15% to 65% (cell migration) and from 11% to 66% (microvascular formation) compared with the controls (Figure VIA and VIB in the online-only Data Supplement). Similar results were obtained when miR-720 was knocked down in EPCs overexpressing miR-31 ( Figure  VIIA and VIIB in the online-only Data Supplement). These findings suggest that the miR720-VASH axis contributes ≈40% to 50% of the miR-31-mediated proangiogenic activities. Knockdown of VASH1 was found not to alter miR-31 or miR-720 levels significantly in EPCs ( Figure VIA in the online-only Data Supplement and Figure 4A ), and a reduction in miR-720 level did not significantly alter the miR-31 level in EPCs ( Figure VIIA , left in the online-only Data Supplement). This supports the hypothesis that the regulation of the miR-31-miR-720-VASH1 axis is unidirectional.
miR-31 Regulates miR-720 Expression Through FAT4 and Planar Cell Polarity Signaling, but Not TBXA2R
In EPCs, overexpression of miR-31 affects the miR720-VASH1 pairing by increasing miR-720 expression ( Figure 5A ). Moreover, knockdown of FAT4, but not TBXA2R, was found to influence the levels of the miR720-VASH1 pair ( Figure 5B ). Knockdown of FAT4 neither altered miR-31 levels nor changed the level of TBXA2R in EPCs (Figure 5B,  left) . Similarly, a reduction in TBXA2R level in EPCs did not affect miR-31 or FAT4 expression ( Figure 5B, right) .
Mouse Fat4 genetically interacts with the planar cell polarity (PCP) proteins Vangl2 (VANGL PCP protein 2) and four-jointed box 1 (Fjx1). 32 In addition, Atn1 and Atn2l modulate Fat4 activity during vertebral arch fusion and renal tubular elongation, respectively. 33 We knocked down 5 human PCP genes in PB EPCs, these were VANGL2, FJX1, ATN1, DVL1, and DVL2, and then examined the endogenous level of miR-720. Knockdown of FJX1, but not of the other 4 genes, resulted in a reduction in the level of miR-720 ( Figure 5C and Figure VIC -VIF in the online-only Data Supplement). Moreover, knockdown of FAT4 increased the abundance of FJX1 mRNA and miR-720 ( Figure 5D ), which indicates that FAT4 is able to repress FJX1 levels and that this consequently leads to an inhibition of miR-720 expression.
FJX1 was shown recently in colorectal carcinoma cells to promote endothelial cell capillary tube formation in a hypoxia-inducible factor 1, α subunit (HIF1α)-dependent manner. 34 We hypothesized that FJX1 in EPCs also regulates miR-720 expression via HIF1α. FIR treatment increased the abundance of HIF1α, as well as those of miR-31/FJX1/miR-720, in EPCs. Nevertheless, knockdown of HIF1α only abolished FIR-induced miR-720 expression ( Figure 5E and Figure VIIA in the online-only Data Supplement). Knockdown of FJX1 but meanwhile overexpressing HIF1α in EPCs restored miR-720 levels ( Figure 5F and Figure VIIB in the online-only Data Supplement). We also overexpressed FJX1 in EPCs but at the same time knocked down endogenous HIF1α levels and found that knocking down HIF1α abolished FJX1-mediated miR-720 expression ( Figure VIIC Figure VIIIA in the online-only Data Supplement) was then examined, and it was found that, although miR-31 overexpression was able to enhance EPC motility and vasculogenesis, a parallel reduction in miR-720 abolished miR-31-mediated angiogenic activity (Figure VIIIA-VIIID in the online-only Data Supplement). Similarly, when FAT4 and miR-720 levels underwent double knockdown in EPCs, the decline in miR-720 expression masked the EPC activation caused by FAT4 reduction ( Figure 5G and 5H and Figure VIIIE and VIIIF in the online-only Data Supplement). Knockdown of miR-720 expression did not alter FAT4 levels in EPCs ( Figure 5G, lanes  1 versus 3) , suggesting that regulation of the miR31-FAT4-miR720 axis is unidirectional.
miR-31 Promotes Blood Flow Recovery in the Ischemic Limbs of Mice
We also evaluated whether miR-31 may boost the in vivo vasculogenesis/angiogenesis activity of diseased EPCs. Limb ischemia was induced by surgery in nude mice 3 days before EPC injection ( Figure 6A ). RNA agomirs of miR-31 were transfected into CAD EPCs 24 hours before transplantation, and overexpression of miR-31 in the transplanted EPCs was verified by qPCR before injection ( Figure 6B ). The CAD EPCs were labeled with the fluorescent marker PKH-26 and then intramuscularly injected locally into the ischemic hindlimb at a site distal to the arterial occlusion site on the third day after surgery. The transfected agomirs still remained in the in vitro cultured EPCs at 14 days after transfection ( Figure IXA in the online-only Data Supplement). The mice were followed for 2 weeks because of the limited lifespan of the transfected miRNA agomirs. As shown in Figure 6C , mice without EPC transplantation (the medium group) showed delayed blood flow recovery after the ischemia surgery compared with the mice that had received EPC therapy using CAD EPCs transfected with scramble oligonucleotides (the Scr control group); this was determined by laser Doppler imaging. In addition and importantly, compared with both the medium and Scr groups, overexpression of miR-31 in the injected EPCs significantly improved blood flow recovery by 90% in the ischemic limbs of the treated mice ( Figure 6C and 6E; n=6 per group) .
To further evaluate the effect of miR-31 on the homing and differentiation to endothelial cells of the injected EPCs, as well as neovascularization/angiogenesis in mice, immunofluorescence staining was conducted on mouse tissue sample at 7 days after EPC injection. Capillaries in the ischemic muscles were visualized using anti-CD31 immunostaining (green, Figure 6D ), whereas injected human EPCs were detected by PKH-26 fluorescence (red, Figure 6D ). Mice that had received the miR-31-transfected EPCs showed the presence of more CD31 + /PKH-26 + double-positive cells (white arrowheads) in the capillaries of the ischemic muscle compared with the medium and Scr control mice ( Figure 6D ; quantitative data in Figure 6F ). The limb ischemia model showed that miR-31 restored the defective angiogenic activities of CAD EPCs.
The importance of miR-31 in FIR-enhanced EPC activities was further evaluated by injecting FIR-treated CAD EPCs in which endogenous miR-31 was blocked. Laser Doppler imaging showed that mice without EPC transplantation (the medium group) had delayed blood flow recovery after the ischemia surgery compared with the mice that had received EPC therapy. Pretreating EPCs with FIR significantly improved blood flow recovery in the ischemic limbs of the treated mice ( Figure XC in the online-only Data Supplement). Nevertheless, miR31-blocked EPCs, although were treated with FIR, failed to rescue limb ischemia in mice ( Figure XC in the online-only Data Supplement; quantitative data in Figure XF in the online-only Data Supplement). Immunofluorescence staining conducted on mouse tissue sample after EPC injection also showed that mice receiving FIR-treated EPCs have more CD31 + /PKH-26 + double-positive cells (white arrowheads) in the capillaries of the ischemic muscle compared with mice receiving control EPCs or FIR-treated, miR-31 knocked down EPCs ( Figure XD 
Discussion
Endothelial dysfunction is considered the first step in the cascade that leads up to CAD. Repair of defective endothelium at the postnatal stage is mainly the responsibility of EPCs, which are derived from the bone marrow. These cells play an important role in vascular homeostasis and compensatory vasculogenesis/angiogenesis because they show plasticity and are able to differentiate into endothelial cells and act MicroRNA-720 (miR-720) plays a crucial role in miR-31 function. A, Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) shows that miR-720 and vasohibin 1 (VASH1) possess inversed correlated expression patterns on miR-31 overexpression. B, Knock down of FAT atypical cadherin 4 (FAT4; left), but not of thromboxane A2 receptor (TBXA2R; right) , alters the expression of the miR-720-VASH1 axis. C, Four-jointed box 1 (FJX1), a planar cell polarity signaling gene, is involved in miR-720 expression. Healthy endothelial progenitor cells (EPCs) were transfected with indicated short hairpin RNAs (shRNAs), and RT-qPCR was performed 2 days after transfection. D, FAT4 inhibits miR-720 expression via repressing FJX1. E, FIR treatment induces hypoxia-inducible factor 1, α subunit (HIF1α) expression in EPCs, and knockdown of HIF1α in FIR-treated EPCs abolished FIR-induced miR-720, but not FJX1, expression. RNA and protein levels of indicated gene were measured by RT-qPCR. F, HIF1α is involved in FJX1-mediated miR-720 induction. EPCs were transfected with indicated expression plasmids or shRNAs, and RT-qPCR was performed 2 days after transfection. G and H, Knocking down miR-720 in FAT4-reduced EPCs (G) abolished the increased cellular activities attributable to the knock down of FAT4. Transwell migration (left) and tube formation (right) assays were conducted (H). Migrated cells or tube length were quantified. All histograms are expressed as the mean±SD. Numbers above bars indicate the relative fold ratios. Significance levels, *P<0.05; **P<0.01; ***P<0.001. siHIF1A indicates small interfering RNA of hypoxia-inducible factor 1, α subunit.
as a source of paracrine proangiogenic factors. The expression profile and functions of miRNAs in healthy EPCs has recently been investigated, 16 ,23 yet the roles of miRNAs in diseased EPCs remain to be defined. In this report, we identified that EPCs exploit the miR-31 pathway as a means of regulating their vasculogenesis/angiogenesis-related activities ( Figure 6G ). This pathway, which is repressed in CAD EPCs, is sufficient for, as well as being critical to, EPC activation, particularly because TBXA2R and FAT4 are direct targets of miR-31. These findings indicate that dysfunction of the miR-31-miR-720 pathway seem to diminish blood vessel repair by impairing vasculogenesis and angiogenesis. This will clearly affect the development and prognosis of cardiovascular disease and other EPC-related syndromes, such as diabetes mellitus-related ischemia. miR-31 is located in the first intron of a host gene, LOC554202, on human chromosome 9p21.3, and its expression is epigenetically regulated by promoter methylation and CCAAT/enhancer binding protein (C/EBP), beta (C/EBP-β) activation. 35, 36 C/EBP-β does not seem to be involved in the studied events because FIR treatment of PB EPCs did not affect the level of C/EBP-β ( Figure XI in the online-only Data Supplement). Furthermore, knockdown of C/EBP-β in healthy EPCs neither affected FIR-mediated miR-31 upregulation nor abolished FIR-stimulated EPC activity ( Figure XI in the online-only Data Supplement). Interestingly, miR-31 is critical for not only blood vessel EC activation (by targeting FAT4 21 ), but also for lymphatic EC differentiation in vitro and in vivo by targeting the critical transcription factor PROX1. 22 It has also been found that miR-31 plays a crucial role in Figure 6 . Transplantation of microRNA-31 (miR-31) (+) endothelial progenitor cells (EPCs) improves blood perfusion in the ischemic hindlimb. A, Schematic representation of experimental design. B, miR-31 levels in transfected EPCs were determined by quantitative polymerase chain reaction and shown as mean±SD. C, Representative images of hindlimb blood flow measured by laser Doppler before operation (Pre-Op), immediately after hindlimb ischemia surgery (Post-Op), and ≤2 weeks after intramuscular injection of endothelial culture medium EGM2 (endothelial cell growth medium-2; medium), coronary artery disease (CAD) EPC transfected with scramble control (Scr), or miR-31 agomirs (miR-31). White arrowheads indicate the functional blood flow at hindlimb before surgery and after EPC treatment. D, Immunofluorescence staining on nude mice tissues 7 days after injection with PKH-26-labeled EPCs. Capillaries in the ischemic muscles were visualized by anti-CD31 immunostaining (green), and injected human EPCs were monitored by PKH-26 fluorescence (red). Mice receiving miR-31-transfected EPCs had more CD31 + /PKH-26 + doublepositive cells (white arrowheads) in ischemic muscle than another 2 control mice groups (Scr and medium). DAPI indicates nuclear staining of live cells (4',6-diamidino-2-phenylindole; blue). Scale bars, 200 μm. E, Quantitative analysis of blood flow expressed as perfusion ratio of the ischemic to the contralateral (nonoperated) hindlimb. *P<0.05, ***P<0.001 compared with control; n=6. F, Quantitative analysis of capillary densities and CD31 + /PKH-26 + double-positive cells in ischemic muscle of mice hindlimb ischemia surgery. HPF indicates high-power field; and N.D., not detectable. Significance levels, **P<0.01; ***P<0.001. n=6. G, A proposed model of EPC angiogenesis activities are regulated by the miR-31-miR-720 pathway. The references that showed that thromboxane A2 receptor (TBXA2R) inhibits vascular endothelial growth factor (VEGF) function are also indicated. tumors 37, 38 in a variety of genetic diseases, such as Duchenne muscular dystrophy, 39 and in the regulation of inflammation mediated by regulatory T cells. 40 miR-31 differential expression is commonly found and has been described as having controversial roles in numerous physiological or pathological conditions. For example, miR-31 acts as a tumor suppressor that inhibits breast cancer metastasis, 37 while it also functions as an oncogenic miRNA in lung cancer. 38 We found miR-31 levels in EPCs and plasma to be closely related to the presence of CAD. miR-31 agomir treatment restores the activity of CAD EPCs to a normal level in vitro and in vivo. If we consider that the restoration of blood supply at an early stage after myocardial infarct to be crucial to patient recovery, these findings may have clinical implications and justify the development to therapies involving inhibition of multiple miRNAs.
Little is known about the expression and the exact function of miR-720. By in silico sequence alignment, it has been suggested that the sequence annotated as miR-720 overlaps that of the mitochondria-encoded tRNA Thr . 29 As a result, miR-720 was removed from miRBase from Release 19, 2012 (see also NCBI Gene ID: 100302198, discontinued on August 2, 2012). However, we have proved by wetlab validation that miR-720 has the functional characteristics of an miRNA, including Dicer1-dependent biogenesis, a physical association with Argonaute proteins, and the ability to repress mRNA transcripts in a sequence-specific manner ( Figure 4H and Figure  IVA and IVB in the online-only Data Supplement). Moreover, pre-miR-720 sequences can also be mapped onto chromosome 3 ( Figure IV in the online-only Data Supplement) as well as to the mitochondrion genome. Our findings indicate that miR-720 is still a functional miRNA, and whether it is derived from either tRNA Thr (by RNA polymerase III) or human chromosome 3 (chr3: 164059155-164059171) does not affect this. Certain miRNAs are transcribed by RNA polymerase III. 41 We found HIF1α is crucial in inducing miR-720 expression, suggesting that RNA polymerase II is, at least in part, involved in the transcription of the miR-720 locus. The present findings support the existence and importance of miR-720 in vivo. As to the function of miR-720, the level of this miRNA is increased in the serum of pregnant women with fetuses with defect neural tubes. 42 miR-720, together with 2 other serum miRNAs, miR-1308 and miR-1246, have been shown to serve as potential biomarkers for myeloma. 43 Use of miR-720 and miR-1308 together is able to distinguish normal healthy controls, as well as patients with unrelated illnesses, from patients with precancerous myeloma and with myeloma. 43 Here, we show for the first time that miR-720 targets VASH1 for achieving its proangiogenic function.
How miR-31 can regulate miR-720 was also explored in this study. We found that FAT4, but not TBXA2R, is the miR-31 target involved in miR-720 regulation ( Figure 5A and 5B). The Fat cadherin protein FAT4 seems to influence both PCP and the Hippo signaling pathways. 32, 44 FAT4 has highest homology to the Drosophila gene atypical cadherin fat (ft), whereas other FAT family members (FAT1-FAT3) are more similar to the second ft-like gene, ft2. 33 Loss of Fat4 in mice disrupts PCP signaling and oriented cell division; this leads to cystic kidney disease, which is partly because of the genetic interactions between Fat4 and the PCP proteins Vangl2 and Fjx1. 32 In Drosophila, the transcriptional corepressor atrophin physically interacts with ft and acts as a component of the Fat signaling involved in planar polarity. The mammalian orthologs of atrophin, Atn1 and Atn2l, modulate Fat4 activity during mouse development. 33 When various human PCP genes are knocked down individually in PB EPCs, namely VANGL2, FJX1, ATN1, DVL1 and DVL2, only the FJX1 knockdown showed any alternation in miR-720 level, in this case reduced expression ( Figure 5C and Figure VIC and VID in the online-only Data Supplement). We further showed that FJX1 is involved in miR-720 upregulation and FAT4 inhibits miR-720 expression via repressing the level of FJX1 ( Figure 5C and 5D ). FJX1 is a notch-inducible secreted ligand that is homologous to the Drosophila four-jointed gene. 45 FJX1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. 34 Interestingly, miR-31 and miR-720 are also expressed at significantly higher levels in colon cancer tissues. 46, 47 Downstream of miR-720 is VASH1, which has been identified as a VEGF-inducible secreted protein in endothelial cells by cDNA microarray analysis 48 and has also been found to belong to a family of N-terminal prolactin fragments that inhibits angiogenesis and vascular functioning. 30, 31, 49 VASH1 induces prolyl hydroxylase-mediated degradation of HIF1α via the induction of prolyl hydroxylase. 50 Expression of VASH1 is low in proliferating endothelial cells at the sprouting front but is high in nonproliferating endothelial cells in newly formed blood vessels that are formed behind the sprouting front, which is where angiogenesis terminates. 51 The presence of VASH1 in endothelial cells is also evident in various cancers, atherosclerotic lesions, age-dependent macular degeneration, diabetic retinopathy, rheumatoid arthritis, and arterial re-endothelialization after denudation. 49 Cancer cellreleased VEGF stimulation in cancer-associated endothelial cells leads to increased expression of EZH2 (enhancer of zeste homolog 2 [Drosophila]), a transcriptional repressor, which thereby causes VASH1 silencing by promoter methylation; this subsequently leads to an increase in angiogenesis. 52 As a result of the proteins antiangiogenic potential, VASH1 has been reported to be a potential biomarker or a possible therapeutic molecule for diseases associated with angiogenesis. 49 Because circulating miRNAs are being considered as novel biomarkers, not only for cardiovascular diseases but also for cancers, 53, 54 serum levels of miR-720, miR-31, and VASH1 may have clinical potential and are an attractive biomarker panel. Their use would allow early diagnosis of relevant diseases and also allow the monitoring of the effectiveness of a relevant therapeutic intervention, such as Avastin as a tumor therapy or statins as a lipid-lowering therapy. miR-31 also achieves its angiogenic role by targeting the receptor of TBXA2. TBXA2, which is a prostanoid, has received great attention because of its involvement in platelet function and the pathogenesis of many cardiovascular diseases, including atherosclerosis and hypertension, 55,56 via interaction with its specific receptor TBXA2R, a G proteincoupled receptor on endothelial cells. 26 TBXA2R signaling is able to inhibit VEGF-induced endothelial cell differentiation and migration. 26, 27 VEGF, therefore, remains a possible mechanism involved in miR-31 angiogenic functioning ( Figure 6G ). However, when miR-31 is overexpressed in healthy EPCs, the levels of VEGF transcript and protein were not changed significantly (not shown). TBXA2R in smooth muscle promotes angiotensin II-induced hypertension, vascular remodeling, and sudden death. 56 Recent experimental findings have indicated that synthetic TBXA2/prostaglandin receptor inhibitors seem to have potent antiplatelet activity with an antiatherosclerotic effect. Such activity has important implications especially when they are used to target clinical conditions associated with an increased production of prostanoids, such as CAD and diabetes mellitus. 27, 55 In the present study we found that miR-31 is an endogenous inhibitor of TBXA2R. Recently, a phase I trial using an miRNA mimic of the tumor suppressor miR-34 (licensed from Marina Biotech) was initiated. This was delivered using a liposomal formulation and used in a trial involving patients with unresectable primary liver cancer or metastatic cancer with liver involvement (http://clinicaltrials.gov/ct2/show/NCT01829971). This application of an miR-31 mimic as a nucleic acid drug for therapeutic purposes is an attractive approach and should see further development.
In this study, we have shown that one of the approaches that can be used with CAD EPCs to restore endogenous miR-31 levels, and therefore angiogenic activity, is FIR irradiation (Figure 3) . FIR treatment represents a noninvasive and convenient therapeutic modality that helps to improve blood flow, endothelial functioning, and EPC activity. 57, 58 FIR therapy has therefore been suggested as a treatment for ischemic lesions and necrosis in skin tissue as a way of improving arteriovenous fistula access flow in hemodialysis patients and as a means of reducing cardiovascular disease frequency. 28, 59 Yet, the molecular mechanisms by which FIR acts remain to be elucidated. It is known that FIR therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. 57 The MEK (mitogen-activated protein kinase kinase)/extracellular signal-regulated kinase signaling pathway, but not the VEGF/ Akt/endothelial NO synthase-dependent pathway, has been shown to be involved in FIR-mediated angiogenesis. 58 In vascular smooth muscle cells, the expression of miR-31, which has a proproliferative effect on vascular smooth muscle cells, is mediated via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. 60 Whether the mitogenactivated protein kinase/extracellular signal-regulated kinase pathway is suppressed in CAD EPCs, thereby resulting in the reduction of miR-31 levels in patients, is under investigation.
Another intriguing possibility is that there may be cellular photosensor(s) by which FIR affects intracellular signaling and changes miRNA expression. It has been shown that a green light-emitting diode irradiation is able to activate directional motility in human orbital fat stem cells via activation of the extracellular signal-regulated kinase/MAP kinase/p38 signaling pathway. 61 Two nonvisual opsins, encephalopsin and short-wave-sensitive opsin 1, serve as the photoreceptors that respond to green light-emitting diode irradiation. 61 Thus, elucidation of the levels and activities of various opsins in healthy and CAD EPCs, as well as roles of opsins in FIRinduced miR-31 expression, EPC migration, and microvascular formation, will help to clarify FIR's mechanisms and its possible applications.
In summary, our research has revealed the existence of a new pathogenesis pathway that regulates EPC self-renewal potential and angiogenic capability in patients with CAD. With these findings, it will be possible to develop not only novel therapeutic modalities that enhance angiogenesis during cardiovascular repair, but also new ways to inhibit angiogenesis when treating cancer. Finally, it should be possible to design new diagnostic panels based on circulating miR-31, miR-720, and VASH1 levels that can help early identification of relevant diseases.
